// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial

Dave Singh - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

fluticasone furoate/umeclidinium/vilanterol

Evaluation of safety, tolerability, pharmacokinetics, and food effect of Danirixin oral tablets in Japanese elderly healthy subjects

Yuki Matsuzawa - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of a conical PEP-mask on dyspnea and exercise endurance in COPD patients: a randomized crossover trial

Chatchai Phimphasak - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Dyspnea

N/A

Indacaterol/glycopyrronium increases lung ventilation in COPD patients as measured by hyperpolarized 3He MRI

Hanns-Christian Tillmann - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Seebri Breezhaler

Blood gas analysis as a marker of severity in acute bronchiolitis

Stefan Unger - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Unsupervised and externally validated clinical cluster analysis from the U-BIOPRED paediatric cohorts

Simone Hashimoto - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Prevalence of physical limitation in COPD: the short physical performance battery (SPPB)

Victoria Benson - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Sleep duration is an independent determinant of metabolic impairment in COPD patients

Nikhil Sahdev - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Development and validation of a screening algorithm for perioperative risk of complications in patients suspected with OSA.

Adil Hasnain - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The impact of different reference standards when estimating the accuracy of tests for diagnosing asthma

Luke Daines - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial

Timm Greulich - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Seebri Breezhaler

Late Breaking Abstract - Safety and immunogenicity of non-typeable H. influenzae (NTHi) adjuvanted vaccine in older adults with chronic obstructive pulmonary disease (COPD)

Tom Wilkinson - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Self-reported intake of fruit and vegetables and risk of chronic obstructive pulmonary disease: a nation-wide twin study

Howraman Meteran - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Associations between PCD-specific health-related quality of life (QOL-PCD) outcomes and clinical measures

Helene Kobbernagel - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The COPD Assessment Test in patients with non-cystic fibrosis bronchiectasisundergoing pulmonary rehabilitation

Aaron Cole - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Cystic Fibrosis

N/A

Multiple Breath Washout (MBW) training, certification and quality control during the iBEST-1 trial in bronchiectasis (BE).

Katherine O'Neill - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Prevalence of comorbidities in established and newly treated patients with COPD according to GOLD 2017 in a UK primary care population

David M. G. Halpin - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Socioeconomic status and lung cancer pathways in southeast London:Friend or Foe?

Amadea Heitmann - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Chest Physiotherapy in patients with Bronchiectasis – what is the current practice in Europe?

Maria Aurora Pinto Mendes - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

From policy to practice in Europe: a TBNET survey on the delivery of LTBI screening and treatment amongst migrants

Matthew Burman - European Respiratory Society (ERS) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Copyright © 2026. QuantiNova All rights reserved